Strategies for cell-mediated immunotherapy of cancer: killing or help?

This publication has 9 references indexed in Scilit:

• Interferon‐activated tumor inhibition in vivo. Small amounts of interferon‐gamma inhibit tumor growth by eliciting host systemic immunoreactivity
  International Journal of Cancer, 1986
• Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
  New England Journal of Medicine, 1985
• Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness.
  The Journal of Experimental Medicine, 1985
• Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.
  The Journal of Experimental Medicine, 1985
• Is immunological tolerance (non-responsiveness) a consequence of interleukin 2 deficit during the recognition of antigen?
  Immunology Today, 1984
• Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones.
  The Journal of Immunology, 1984
• The Murine Antitumor Immune Response and Its Therapeutic Manipulation
  Published by Elsevier ,1984
• Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.
  The Journal of Experimental Medicine, 1982
• Cell-Mediated Cytotoxicity, Allograft Rejection, and Tumor Immunity
  Published by Elsevier ,1974